Expert opinion on drug metabolism & toxicology · 2016
Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anderson Rose, Hayes Jennifer, Stephens Jeffrey W
Аннотация
INTRODUCTION: Dipeptide peptidase-4 (DPP-4) inhibitors such as saxagliptin are established and efficacious oral therapies in the management of type 2 diabetes. These agents have the potential to confer significant benefits in glycemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes.
AREAS COVERED: This review examines the pharmacokinetics, efficacy and tolerability of saxagliptin for the management of type 2 diabetes.
EXPERT OPINION: Saxagliptin is routinely used in the management of type 2 diabetes as monotherapy, and in combination with other oral agents and insulin. Robust clinical trials have shown consistent improvements in glycated hemoglobin, fasting and postprandial glucose levels, with few adverse effects. The agent is well tolerated with low rates of hypoglycemia in the absence of insulin or sulphonylurea therapy.
AREAS COVERED: This review examines the pharmacokinetics, efficacy and tolerability of saxagliptin for the management of type 2 diabetes.
EXPERT OPINION: Saxagliptin is routinely used in the management of type 2 diabetes as monotherapy, and in combination with other oral agents and insulin. Robust clinical trials have shown consistent improvements in glycated hemoglobin, fasting and postprandial glucose levels, with few adverse effects. The agent is well tolerated with low rates of hypoglycemia in the absence of insulin or sulphonylurea therapy.
Предметные рубрики MeSH
AdamantaneBlood GlucoseClinical Trials, Phase III as TopicDiabetes Mellitus, Type 2DipeptidesDipeptidyl-Peptidase IV InhibitorsDose-Response Relationship, DrugDrug Therapy, CombinationGlycated HemoglobinHumansInsulinMeta-Analysis as TopicPostprandial PeriodRandomized Controlled Trials as TopicRisk FactorsSulfonylurea CompoundsTreatment Outcome